Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.1K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

3.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.4K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.4K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.0K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smartphone App-Based Eating Behavior Monitoring and Feedback Intervention for Glucocorticoid-Induced Appetite Increase in Patients With Systemic Lupus Erythematosus: Protocol for a Pilot Randomized Controlled Trial.

JMIR research protocols·2025
Same author

Unplanned Hospitalization Due to All-Cause Morbidity and Its Real-World Management Practices in Patients With Fontan Circulation.

Journal of the American Heart Association·2025
Same author

Smartphone App-based Eating Behavior Monitoring and Feedback Intervention for Glucocorticoid-induced Appetite Increase in Patients With Systemic Lupus Erythematosus: Protocol for a Pilot Randomized Controlled Trial.

JMIR research protocols·2025
Same author

Left Lower Lobectomy for Lung Cancer Complicated by Unilateral Absence of the Left Pulmonary Artery: A Case Report.

Surgical case reports·2025
Same author

Association between sedentary behavior and sleep quality among urban white-collar workers with or at risk of metabolic syndrome: a secondary analysis of a randomized 3-month workplace lifestyle intervention trial.

Journal of occupational health·2025
Same author

An 11-year single-center experience of Norwood procedures in the neonates with hypoplastic left heart syndrome and variants.

Annals of pediatric cardiology·2025

Related Experiment Video

Updated: Feb 23, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K

Genetic abnormalities in core binding factor acute myeloid leukemia.

Yuichi Ishikawa1

  • 1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|September 9, 2017
PubMed
Summary

Core binding factor acute myeloid leukemia (CBF-AML) has a favorable risk but often relapses. Additional genetic mutations, beyond core fusion genes, are crucial for its development and require comprehensive analysis for better treatment strategies.

Keywords:
CBF-AMLGenetic alterations

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.9K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Related Experiment Videos

Last Updated: Feb 23, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.9K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Area of Science:

  • Hematology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) is a complex cancer with prognosis determined by genetic alterations.
  • Core binding factor AML (CBF-AML), characterized by specific chromosomal translocations like t(8;21) and inv16, is classified as favorable-risk.
  • Despite favorable classification, a significant percentage of CBF-AML patients experience relapse, indicating underlying complexities beyond the primary genetic drivers.

Purpose of the Study:

  • To investigate the genetic heterogeneity of CBF-AML beyond the defining fusion genes.
  • To explore the role of additional mutations (e.g., in KIT, FLT3, ASXL2) in leukemogenesis within CBF-AML.
  • To emphasize the necessity of comprehensive genetic analysis for accurate risk stratification and improved treatment strategies in CBF-AML.

Main Methods:

  • Analysis of chromosomal and genetic alterations in CBF-AML patient samples.
  • Identification of fusion genes (RUNX1-RUNX1T1, CBFB-MYH11) resulting from characteristic translocations.
  • Detection of additional somatic mutations in genes such as KIT, FLT3, N-RAS, ASXL2, ZBTB7A, CCND2, and DHX15.

Main Results:

  • CBF-AML arises from specific fusion genes (RUNX1-RUNX1T1 or CBFB-MYH11) but requires cooperating mutations for full leukemogenesis.
  • Activating kinase mutations (KIT, FLT3, N-RAS) frequently co-occur and are critical for disease development.
  • Recent studies identified mutations in ASXL2, ZBTB7A, CCND2, and DHX15 in t(8;21) AML, though their significance is still under investigation.

Conclusions:

  • CBF-AML is a genetically diverse disease where combinations of genomic abnormalities drive leukemogenesis.
  • Comprehensive genetic profiling is essential for understanding CBF-AML heterogeneity and refining risk stratification.
  • Further research into specific genetic combinations and clonal evolution is needed to develop targeted therapies for relapsed CBF-AML.